Q3 2025 Aptargroup Inc Earnings Call Transcript
Key Points
- AptarGroup Inc (ATR) reported a 6% increase in reported sales and a 1% growth in core sales for the third quarter.
- The pharma segment saw a 2% increase in core sales, driven by strong demand for proprietary drug delivery systems and injectables.
- The company signed an agreement to acquire Soma Plus, enhancing its footprint in Brazil and positioning it for growth in the oral dosing and nutraceutical markets.
- AptarGroup Inc (ATR) continues to focus on innovation, with recent technology launches and partnerships in the pharma segment, including FDA approvals and new clinical trials.
- The company increased its quarterly dividend by nearly 7% to $0.48 per share, highlighting its commitment to returning capital to shareholders.
- The consumer healthcare segment experienced an 11% decline in core sales due to lower sales of nasal decongestants and nasal saline.
- Beauty segment core sales were flat, with declines in fragrance, facial skin care, and color cosmetics, primarily in North America.
- The closure segment saw a 1% decrease in core sales, impacted by lower tooling sales and pass-throughs of lower resin prices.
- AptarGroup Inc (ATR) faces headwinds in its emergency medicine portfolio, with expected revenue declines due to elevated inventory levels at a large customer.
- The company incurred atypical litigation costs of approximately $4 million, impacting net income and highlighting ongoing legal challenges.
Ladies and gentlemen, thank you for standing by. Welcome to Avatar's 20253rd quarter results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session.
Introducing today's conference call is Mrs. Mary Scafidis, Senior Vice President, Investor Relations and communications. Please go ahead.
Thank you. Hello everyone, and thanks for being with us today. Our speakers for the call are Stefanannda, our President and CEO, and Vanessa Cannu, our executive Vice President and CFO.
A press release and accompanying slide deck have been posted on our website under the investor relations page.
During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure, and the reconciliations are set forth in the press release. Please refer to the press release disseminated yesterday for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
